Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 14:11:643490.
doi: 10.3389/fonc.2021.643490. eCollection 2021.

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens

Cirino Botta  1 , Enrica Antonia Martino  1 , Concetta Conticello  2 , Francesco Mendicino  1 , Ernesto Vigna  1 , Alessandra Romano  3 , Giuseppe Antonio Palumbo  3 , Claudio Cerchione  4 , Giovanni Martinelli  4 , Fortunato Morabito  5 , Francesco Di Raimondo  3 , Massimo Gentile  1
Affiliations

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens

Cirino Botta et al. Front Oncol. .
No abstract available

Keywords: bortezomib; carfilzomib; daratumumab; isatuximab; lenalidomide; myeloma; network meta analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Network plot showing all the direct comparisons and the number of patients included in each node (i.e. the total number of patients receiving the treatment indicated in the node). (B, C) forest-plots indicating the efficacy of each regimen (in terms of hazards ratio (HR) and 95% confidence intervals) by using VD as comparator arms. (D) Ranking charts of all the evaluated regimens based on the P-score and grouped according to previous exposition or resistance to lenalidomide. VD, bortezomib-dexamethasone; DVD, daratumumab-VD; SVD, selinexor-VD; PVD, pomalidomide-VD; KD, carfilzomib-dexamethasone; KdD, daratumumab-KD; IKD, isatuximab-KD.
See this image and copyright information in PMC

References

    1. Botta C, Ciliberto D, Rossi M, Staropoli N, Cuce M, Galeano T, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv (2017) 1:455–66. 10.1182/bloodadvances.2016003905 - DOI - PMC - PubMed
    1. Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M. Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. Curr Hematol Malig Rep (2019) 14:187–96. 10.1007/s11899-019-00507-x - DOI - PubMed
    1. Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, et al. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Adv (2019) 3:4095–103. 10.1182/bloodadvances.2019000539 - DOI - PMC - PubMed
    1. Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol (2015) 15:58. 10.1186/s12874-015-0060-8 - DOI - PMC - PubMed
    1. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet (2020) 396:186–97. 10.1016/S0140-6736(20)30734-0 - DOI - PubMed

LinkOut - more resources